<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Trials</title>
	<atom:link href="http://www.tapanray.in/tag/trials/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Reticence Around Unveiling Clinical Trials</title>
		<link>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reticence-around-unveiling-clinical-trials</link>
		<comments>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/#comments</comments>
		<pubDate>Mon, 17 Oct 2016 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[legalities]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reticence]]></category>
		<category><![CDATA[Semler]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unveiling]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7886</guid>
		<description><![CDATA[While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients &#8230; <a href="http://www.tapanray.in/reticence-around-unveiling-clinical-trials/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: An Emerging Opportunity in The Gray Area Between Pharma And Nutrition</title>
		<link>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition</link>
		<comments>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/#comments</comments>
		<pubDate>Mon, 17 Nov 2014 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[A.T.Kearney]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[Ayush]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Coca]]></category>
		<category><![CDATA[Cola]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[dietary]]></category>
		<category><![CDATA[EBM]]></category>
		<category><![CDATA[EBN]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Frost&Sullivan]]></category>
		<category><![CDATA[FSSA]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[Homeopathy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naturopathy]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[nutrition]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Siddha]]></category>
		<category><![CDATA[supplement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unani]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Yoga]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6190</guid>
		<description><![CDATA[Close association between nutrition and health has assumed a historical relevance. Growing pieces of evidence, even today, suggests that nutritional intervention with natural substances could play an important role, especially in the preventive healthcare. The World Health Organization (WHO) too &#8230; <a href="http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court Suspends New Drug Trials in India&#8230;Time to Shape Up?</title>
		<link>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up</link>
		<comments>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/#comments</comments>
		<pubDate>Mon, 14 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advisory]]></category>
		<category><![CDATA[AE]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[ceravix]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[CTs]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[deaths]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[expert]]></category>
		<category><![CDATA[exploitation]]></category>
		<category><![CDATA[gardasil]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mechanisms]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[SAE]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[SC]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[standing Committee]]></category>
		<category><![CDATA[stops]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRC]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3839</guid>
		<description><![CDATA[On September 30, 2013, with a damning stricture to the Drug Regulator, the Supreme Court, in response to a Public Interest Litigation (PIL) filed by the NGO Swasthya Adhikar Manch, stayed approvals for 162 applications for local Clinical Trials (CTs) of new &#8230; <a href="http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond &#8216;The Magic Moment&#8217; of New Drug Marketing Approval</title>
		<link>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-magic-moment-of-new-drug-marketing-approval</link>
		<comments>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/#comments</comments>
		<pubDate>Mon, 24 Jun 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adaptive]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[AL]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[focused]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredient]]></category>
		<category><![CDATA[Jangle]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhaseIV]]></category>
		<category><![CDATA[pst]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[reimbursement]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[surveillance]]></category>
		<category><![CDATA[Tacfidera]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncontrolled]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2394</guid>
		<description><![CDATA[“Uncontrolled clinical trials are causing havoc to human life. There are so many legal and ethical issues involved with clinical trials and the government has not done anything so far.” This is exactly what the Supreme Court of India observed &#8230; <a href="http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Ten Step Strategy Prescribed</title>
		<link>http://www.tapanray.in/a-ten-step-strategy-prescribed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-ten-step-strategy-prescribed</link>
		<comments>http://www.tapanray.in/a-ten-step-strategy-prescribed/#comments</comments>
		<pubDate>Mon, 24 Dec 2012 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[prescribed]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ten]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1101</guid>
		<description><![CDATA[In India, there are various hurdles to address the healthcare issues in a comprehensive way. Though, these do not seem to be insurmountable, the country needs a clear time-bound grand strategy to squarely address this vexing concern, which also has its &#8230; <a href="http://www.tapanray.in/a-ten-step-strategy-prescribed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-ten-step-strategy-prescribed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hysteria on Corporate Lobbying in India</title>
		<link>http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hysteria-on-corporate-lobbying-in-india</link>
		<comments>http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/#comments</comments>
		<pubDate>Mon, 17 Dec 2012 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[hysteria]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1104</guid>
		<description><![CDATA[The &#8216;hysteria&#8217; on &#8216;Corporate Lobbying&#8217; influencing the key policy decisions of India, reverberated in the corridors of power of the Indian Parliament last week with consequent media attraction and triggering a raging public debate. On Monday, December 10, 2012 the Upper &#8230; <a href="http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A NEW Study on Ballooning Pharma R&amp;D Cost: Exploring a Sustainable Model for Greater Patients’ Access</title>
		<link>http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access</link>
		<comments>http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/#comments</comments>
		<pubDate>Mon, 10 Dec 2012 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1057</guid>
		<description><![CDATA[The high-decibel debate on increasing prices for patented drugs affecting patients’ access to innovative medicines gets a new fuel. A brand new study dated December 2012 carried out by the Office of Health Economics (OHE), UK, which was partly supported by a &#8230; <a href="http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Revocation and Denial of Patents on Patentability Ground in India: The Fallout and the Road Ahead</title>
		<link>http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead</link>
		<comments>http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/#comments</comments>
		<pubDate>Mon, 03 Dec 2012 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[denial]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1060</guid>
		<description><![CDATA[On November 26, 2012, the Intellectual Property Appellate Board (IPAB) reportedly denied patent protection for AstraZeneca’s anti-cancer drug Gefitinib on the ground that the molecule lacked invention. The report also states that AstraZeneca suffered its first setback on Gefitinib in June 2006, &#8230; <a href="http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
